CytoDyn (CYDY) Q3 2026 earnings summary

Executive summary

• Focused on clinical development of leronlimab for solid-tumor oncology, with ongoing Phase II trials and plans for additional studies and a long-acting version of the drug.

• Strategy includes pursuing non-dilutive financing, such as licensing and partnerships, to supplement capital needs.

• Operating results fluctuate due to clinical trial progress, regulatory activities, and legal proceedings.

Financial highlights

• Net loss of $4.7 million for the quarter ended February 28, 2026, compared to a net loss of $4.8 million in the prior year quarter.

• Nine-month net loss of $32.8 million, compared to net income of $9.7 million in the prior year, which included a one-time $25 million clinical expense recovery.

• Cash and cash equivalents were $15.7 million as of February 28, 2026, up from $11.9 million at May 31, 2025.

• Operating expenses increased 57% year-over-year for the quarter, primarily due to higher research and development costs.

• Research and development expenses rose 87% for the quarter, driven by increased clinical trial activity.

Outlook and guidance

• Significant additional funding is required to execute the business strategy, including further clinical trials and regulatory submissions.

• Plans to continue research and development of leronlimab and pursue regulatory approval for commercialization.

• Ongoing efforts to secure capital through equity, debt, and partnership arrangements.